Business | Monday March 18, 2013
BDR Pharmaceuticals International Pvt Ltd has applied to the patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, Dasatinib, through a so-called compulsory license mechanism, a BDR executive said on Monday.
www.ndtv.com/business